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Purpose of the study
To compare the virological, immunological and clinical
response to three boosted double protease inhibitor (PI)
regimens of saquinavir and ritonavir in combination with
lopinavir (LOPSAQ), atazanavir (ATSAQ) or fosamprena-
vir (FOSAQ) without reverse transcriptase inhibitors (RTI)
in HIV-positive patients with limited RTI treatment
options.
Methods
Comparative cohort observation of pre-treated patients (n
= 279) who had experienced therapy failure on their RTI-
regimen due to resistance and/or toxicity. Patients with PI-
resistance mutations or RTI toxicity underwent a struc-
tured treatment interruption until virus reverted to wild-
type or resolution of toxicity symptoms.
Summary of results
In this critical patient collective, the proportion of
patients still on observational regimens at week 48 was
overall 187 out of 279 patients (67%) and 133/198 for
LOPSAQ, 44/67 for ATSAQ and 10/14 for FOSAQ. The
overall response to treatment at week 48 was 52% for
LOPSAQ, 57% for ATSAQ and 64% for FOSAQ (ITT).
Compared to baseline, median viral loads (log10 copies/
mL, ITT-analysis) decreased through week 48 from 4.98 to
1.60 (LOPSAQ), from 4.83 to 1.60 (ATSAQ), and from
4.51 to 1.60 (FOSAQ), respectively. Median CD4 increase
in cells/μL at week 48 was comparably high for LOPSAQ
(+140) and ATSAQ (+141; p = 0.919), but lower for
FOSAQ group (+14; p < 0.01 vs. LOPSAQ; p = 0.013 vs.
ATSAQ), in LOCF-analysis accordingly (see Figure 1).
Conclusion
The virologic response to treatment was similar in
between the three combinations of LOPSAQ, ATSAQ or
FOSAQ, respectively. This RTI-sparing, PI-only antiretro-
viral therapy may be an effective option for treatment
experienced patients after RTI-failure due to toxicity or
resistance. The immunological outcome of both LOPSAQ
and ATSAQ seems to be superior to FOSAQ. For exten-
sively pre-treated patients at low CD cell counts, this his-
torical option of a double-PI only combination regimen is
today extended by new antiretroviral classes.
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Proportion of patients below the detection limit (<50 copies/mL) and CD4 cell count-development during 48 weeks on three 
different boosted double protease inhibitor regimens – without further additional antiretrovirals.
